This study investigates the clinical effects and safety of subcutaneous Copper Histidinate treatment for patients diagnosed with Menkes disease and previously treated at NICHD under protocol 09-CH-005
Clinical Trial Grant
Administered By
Pediatrics, Medical Genetics
Awarded By
Sentynl Therapeutics, Inc.
Start Date
April 23, 2025
End Date
October 31, 2027
Administered By
Pediatrics, Medical Genetics
Awarded By
Sentynl Therapeutics, Inc.
Start Date
April 23, 2025
End Date
October 31, 2027